Chanchamayo Peru (Coffea arabica)

Chanchamayo Peru (Coffea arabica) is a specialty coffee cultivar from Peru's Chanchamayo Valley containing standard coffee bioactives like caffeine and chlorogenic acids. This cultivar lacks specific clinical research, with health effects presumed similar to other arabica varieties.

Origin & History

Chanchamayo Peru (Coffea arabica) is a high-quality coffee cultivar grown in the Chanchamayo Valley on the eastern slopes of Peru's Andes Mountains at altitudes around 5,000 feet (1,500 meters). These beans are typically wet-processed through fermentation and often cultivated organically by small-scale farmers, resulting in a medium-bodied coffee with chocolate, nut, and citrus notes.

Historical & Cultural Context

Chanchamayo Peru coffee has no documented historical use in traditional medicine systems according to the research. It is primarily recognized for culinary and export purposes in modern Peruvian agriculture, with production emphasizing high-altitude, organic farming for flavor quality rather than medicinal applications.

Health Benefits

• No specific health benefits documented - no clinical trials or biomedical studies found for this cultivar
• General coffee compounds implied but not quantified - cultivar lacks specific research
• No evidence for therapeutic effects - search results focus only on culinary/agricultural aspects
• No pharmacological data available - no mechanisms or pathways studied
• No standardized extracts or supplements exist - only traditional beverage preparation documented

How It Works

As a Coffea arabica cultivar, Chanchamayo Peru contains caffeine (typically 1.2-1.5%) which blocks adenosine receptors in the central nervous system. Chlorogenic acids (3-5%) may inhibit glucose-6-phosphatase and promote antioxidant activity through free radical scavenging pathways.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found for Chanchamayo Peru coffee as a biomedical ingredient. The research dossier explicitly states that no PubMed PMIDs or studies on health outcomes exist for this specific cultivar variant.

Clinical Summary

No clinical trials have specifically examined Chanchamayo Peru coffee cultivar for health outcomes. Research focuses exclusively on agricultural yield, flavor profiles, and growing conditions rather than biomedical applications. Health benefits are extrapolated from general arabica coffee research, which limits evidence-based conclusions. The cultivar's therapeutic potential remains uncharacterized in controlled human studies.

Nutritional Profile

Chanchamayo Peru (Coffea arabica) shares the general nutritional composition of Arabica coffee beans, with cultivar-specific quantification absent from published literature. Based on Arabica species data: green (unroasted) beans contain approximately 10-12% moisture, 11-13% crude protein (including free amino acids such as glutamic acid, aspartic acid, and asparagine at 0.5-1.0 g/100g each), 15-17% total lipids (dominated by diterpenes cafestol and kahweol at 0.5-1.2% of dry weight, along with linoleic acid comprising ~40% of fatty acid fraction), and 38-42% total carbohydrates (predominantly sucrose at 6-9% in green beans, degrading significantly upon roasting). Chlorogenic acids (primarily 5-caffeoylquinic acid) are the dominant bioactive polyphenols, estimated at 6-10% of green bean dry weight for Arabica varieties grown at high altitude — Chanchamayo's elevation (1,500-2,000 m) suggests concentrations toward the higher end of this range. Caffeine content is typically 1.0-1.4% dry weight for Arabica. Trigonelline is present at 0.6-1.2% dry weight, partially converting to niacin (vitamin B3) upon roasting, yielding approximately 10-40 mg niacin per 200 mL brewed cup. Roasted beans retain trace minerals including potassium (~1,600-2,000 mg/100g dry), magnesium (~200 mg/100g dry), and manganese (~1-3 mg/100g dry). Bioavailability of chlorogenic acids from brewed coffee is estimated at 30-50% absorption in the small intestine; cafestol and kahweol are largely retained in paper-filtered preparations (<1 mg/cup) but elevated in unfiltered methods (3-6 mg/cup). No cultivar-specific compositional analysis for Chanchamayo Peru has been identified in peer-reviewed literature.

Preparation & Dosage

No clinically studied dosage ranges are available for Chanchamayo Peru coffee in extract, powder, or standardized forms. Traditional use involves brewing whole beans, but no biomedical standardization or therapeutic dosing has been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of biomedical research

Safety & Interactions

Safety profile presumed similar to other arabica coffees based on comparable caffeine content. Typical coffee contraindications likely apply including pregnancy limitations, interactions with stimulant medications, and potential anxiety exacerbation. No cultivar-specific adverse effects documented due to absence of clinical safety studies. Standard coffee consumption guidelines of 400mg caffeine daily maximum would apply.